Clinical Trial Update: A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of selinexor, temozolomide, and an anti-PD-1 antibody for relapsed/refractory primary central nervous syst…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Anti-PD-1 antibody
• Temodar (Temozolomide)
• XPOVIO (selinexor)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Relapsed/Refractory Primary Central Nervous System Lymphoma | Phase 1, Phase 2 | Status: RECRUITING